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N-(3-phenylamino-4-pyridinyl)trifluoromethanesulphonamide or FJ29 is a pyridine analogue of 
nimesulide, a COX-2 preferential inhibitor that was withdrawn from market because of liver toxicity. 
Compound FJ29 showed in vitro higher cyclooxygenases (COXs) inhibitory potency than nimesulide 
as well as an important anti-inflammatory activity in vivo. However, this compound expressed a rather 
low COX-2 (type 2 cyclooxygenase) selectivity ratio. So, we realised the synthesis of new pyridine 
derivatives of nimesulide while keeping the N-(3-phenylamino-4-pyridinyl)sulphonamide scaffold in 
order to obtain original compounds exhibiting a potent COXs inhibitory activity with a COX-2 
preferential profile. The COXs inhibitory potency of synthesized compounds was evaluated on a 
human whole blood model while the anti-inflammatory activity was determined in a rat lambda 
carrageenan-induced pleurisy model. Drug plasmatic concentration obtained at the end of the in vivo 
experiments was determined by means of a SPE-LC (Solid Phase Extraction – Liquid 
Chromatography) method. Various experimentations allowed us to identify compounds exhibiting a 
strong COXs inhibitory activity in vitro with an important anti-inflammatory potency in vivo. 
Plasmatic assays also showed a different pharmacokinetic profile between nimesulide and its pyridine 
analogues.       
